Download PDF
Semin Thromb Hemost 2012; 38(05): 530-534
DOI: 10.1055/s-0032-1305783
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Viral Hepatitis and Thrombosis: A Narrative Review

Alessandro Squizzato
1   Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy
2   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Victor E.A. Gerdes
2   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
3   Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
07 March 2012 (online)

    Permissions and Reprints

Abstract

Venous thromboembolism (VTE) is a multicausal disease. Among minor risk factors, acute infections in general are associated with a transient increased risk of VTE. However, acute hepatitis is usually not reported as a potential risk factor for VTE. Recent studies suggest a possible role of viral hepatitis in the development of VTE and, in particular, of portal vein thrombosis. In this narrative review, we will discuss the possible pathogenetic roles of cytomegalovirus, Epstein-Barr virus, and hepatitis A, B, and C viruses in VTE occurrence, and clinical evidence supporting this hypothesis. The hemostatic state in chronic liver disease and the role of coagulation in liver fibrosis will also be discussed.

Keywords

hepatitis - thrombosis - cytomegalovirus - Epstein-Barr virus - hepatitis A, B and C virus
 

  • References

  • 1 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353 (9159) 1167-1173
    CrossrefPubMedGoogle Scholar
  • 2 Denninger MH, Chaït Y, Casadevall N , et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31 (3) 587-591
    CrossrefPubMedGoogle Scholar
  • 3 Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367 (9516) 1075-1079
    CrossrefPubMedGoogle Scholar
  • 4 Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60 (1) 26-39
    CrossrefPubMedGoogle Scholar
  • 5 Squizzato A, Gerdes VEA, Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005; 93 (3) 403-410
    PubMedGoogle Scholar
  • 6 Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB ; for the Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39 (1) 2-17
    CrossrefPubMedGoogle Scholar
  • 7 Centers for Disease Control and Prevention (CDC). Atlanta. Available at: http://www.cdc.gov . Accessed Sept 14, 2011–09–14
    PubMedGoogle Scholar
  • 8 Chanarin I, Walford DM. Thrombocytopenic purpura in cytomegalovirus mononucleosis. Lancet 1973; 2 (7823) 238-239
    PubMedGoogle Scholar
  • 9 Squizzato A, Ageno W, Cattaneo A, Brumana N. A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2007; 44 (2) e13-e16
    CrossrefPubMedGoogle Scholar
  • 10 Delbos V, Abgueguen P, Chennebault JM, Fanello S, Pichard E. Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect 2007; 54 (1) e47-e50
    CrossrefPubMedGoogle Scholar
  • 11 Justo D, Finn T, Atzmony L, Guy N, Steinvil A. Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med 2011; 22 (2) 195-199
    CrossrefPubMedGoogle Scholar
  • 12 Mashav N, Saar N, Chundadze T, Steinvil A, Justo D. Epstein-Barr virus-associated venous thromboembolism: a case report and review of the literature. Thromb Res 2008; 122 (4) 570-571
    CrossrefPubMedGoogle Scholar
  • 13 Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31 (4) 256-263
    CrossrefPubMedGoogle Scholar
  • 14 Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006; 28: 101-111
    CrossrefPubMedGoogle Scholar
  • 15 Williams R. Global challenges in liver disease. Hepatology 2006; 44 (3) 521-526
    CrossrefPubMedGoogle Scholar
  • 16 Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008; 103 (5) 1283-1297 , quiz 1298
    CrossrefPubMedGoogle Scholar
  • 17 Green AJ, Novak LJ. Thrombophlebitic prodrome in hepatitis. N Engl J Med 1971; 285 (23) 1322
    PubMedGoogle Scholar
  • 18 Shoenfeld Y. Systemic antiphospholipid syndrome. Lupus 2003; 12 (7) 497-498
    CrossrefPubMedGoogle Scholar
  • 19 Biron C, Andreani H, Blanc P. Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med 1998; 131: 243-250
    CrossrefPubMedGoogle Scholar
  • 20 Violi F, Ferro D, Basili S , et al. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med 1995; 43 (6) 550-554
    PubMedGoogle Scholar
  • 21 Prieto J, Yuste JR, Beloqui O , et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996; 23 (2) 199-204
    CrossrefPubMedGoogle Scholar
  • 22 Daniels AH, Wilson CL, Harrison RA. Hepatitis C-associated leukocytoclastic vasculitis with anticardiolipin antibodies causing penile necrosis and deep venous thrombosis in the absence of cryoglobulinemia. J Hosp Med 2008; 3 (2) 170-172
    CrossrefPubMedGoogle Scholar
  • 23 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112 (9) 682-698
    CrossrefPubMedGoogle Scholar
  • 24 Mangia A, Margaglione M, Cascavilla I , et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999; 94 (10) 2983-2987
    CrossrefPubMedGoogle Scholar
  • 25 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (2) 147-156
    CrossrefPubMedGoogle Scholar
  • 26 Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol 2011; 35 (8–9) 526-533
    CrossrefPubMedGoogle Scholar
  • 27 Wright M, Goldin R, Hellier S , et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52 (8) 1206-1210
    CrossrefPubMedGoogle Scholar
  • 28 Levy GA, Liu M, Ding J , et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 2000; 156 (4) 1217-1225
    CrossrefPubMedGoogle Scholar
  • 29 Marsden PA, Ning Q, Fung LS , et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003; 112 (1) 58-66
    PubMedGoogle Scholar
  • 30 Nicolò M, Artioli S, La Mattina GC, Ghiglione D, Calabria G. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin. Eur J Ophthalmol 2005; 15 (6) 811-814
    PubMedGoogle Scholar
  • 31 Sene D, Touitou V, Bodaghi B , et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13 (22) 3137-3140
    PubMedGoogle Scholar
  • 32 Murata M, Tamura Y, Ohsawa M, Hirano T, Matsuo T, Murata T. Central retinal vein occlusion in hypertensive patients with chronic hepatitis C treated with interferon alpha and ribavirin. Jpn J Ophthalmol 2008; 52 (6) 511-513
    CrossrefPubMedGoogle Scholar
  • 33 Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 2009; 53 (6) 598-602
    CrossrefPubMedGoogle Scholar
  • 34 Balderramo DC, García O, Colmenero J, Espinosa G, Forns X, Ginès P. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. Dig Liver Dis 2009; 41 (7) e4-e7
    CrossrefPubMedGoogle Scholar
  • 35 Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998; 93 (12) 2441-2444
    CrossrefPubMedGoogle Scholar
  • 36 Nadir A, Amin A, Chalisa N, van Thiel DH. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J Viral Hepat 2000; 7 (6) 466-470
    CrossrefPubMedGoogle Scholar
  • 37 Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9 (9) 1713-1723
    CrossrefPubMedGoogle Scholar
  • 38 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD ; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49 (3) 1017-1044
    CrossrefPubMedGoogle Scholar